Activities of garenoxacin (BMS-284756) and other agents against anaerobic clinical isolates

被引：15

作者：

Hecht, DW

Osmolski, JR

机构：

[1] Loyola Univ, Med Ctr, Maywood, IL 60153 USA

[2] Edward Hines Jr Vet Adm Hosp, Hines, IL 60141 USA

来源：

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY | 2003年 / 47卷 / 03期

关键词：

D O I：

10.1128/AAC.47.3.910-916.2003

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

A total of 590 clinical isolates consisting of 33 species of both gram-positive and gram-negative anaerobes were collected from nine centers in the Chicago area in 1998-1999. The largest number of isolates (330 isolates, 56%) belonged to the Bacteroides group. Isolates were tested by agar dilution against garenoxacin (BMS-284756, T-3811 ME), trovafloxacin, moxifloxacin, clindamycin, imipenem, piperacillin-tazobactam, and cefoxitin. All but one species (2% of Bacteroides vulgatus isolates) were fully susceptible to piperacillin-tazobactam and imipenem. A number of species were resistant to clindamycin. Among the fluoroquinolones, garenoxacin and trovafloxacin had an MIC at which 90% of the isolates tested were inhibited of <4 μg/ml for all but two species (Fusobactetium mortifierum/varium and Peptostreptococcus anaerobius).

引用

收藏

页码：910 / 916

页数：7

相关论文

共 27 条

[1] Multicenter survey of the changing in vitro antimicrobial susceptibilities of clinical isolates of Bacteroides fragilis group, Prevotella, Fusobacterium, Porphyromonas, and Peptostreptococcus species [J].

Aldridge, KE ;

Ashcraft, D ;

Cambre, K ;

Pierson, CL ;

Jenkins, SG ;

Rosenblatt, JE .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (04) :1238-1243

[2]

ALDRIDGE KE, 1995, AM J SURG, V169, pS2

[3] Quinolone activity against anaerobes [J].

Appelbaum, PC .

DRUGS, 1999, 58 (Suppl 2) :60-64

[4] Antimicrobial activities of BMS-284756 compared with those of fluoroquinolones and β-lactams against gram-positive clinical isolates [J].

Bassetti, M ;

Dembry, LM ;

Farrel, PA ;

Callan, DA ;

Andriole, VT .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (01) :234-238

[5] Activities of new antimicrobial agents (trovafloxacin, moxifloxacin, sanfetrinem, and quinupristin-dalfopristin) against Bacteroides fragilis group:: Comparison with the activities of 14 other agents [J].

Betriu, C ;

Gómez, M ;

Palau, ML ;

Sánchez, A ;

Picazo, JJ .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (09) :2320-2322

[6] Anti-anaerobic activity of antibacterial agents [J].

Bryskier, A .

EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (02) :239-267

[7] Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms [J].

Ednie, LM ;

Jacobs, MR ;

Appelbaum, PC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) :2459-2462

[8] Prevalence and degree of expression of the carbapenemase gene (cfiA) among clinical isolates of Bacteroides fragilis in Nottingham, UK [J].

Edwards, R ;

Hawkyard, CV ;

Garvey, MT ;

Greenwood, D .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (02) :273-276

[9] Comparative antimicrobial spectrum and activity of BMS284756 (T-3811, a desfluoroquinolone) tested against 656 Enterobacteriaceae, including preliminary in vitro susceptibility test comparisons and development [J].

Fix, AM ;

Pfaller, MA ;

Biedenbach, DJ ;

Beach, ML ;

Jones, RN .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2001, 18 (02) :141-145

[10] Prevalence of β-lactamase-producing strains among 149 anaerobic gram-negative rods isolated from periodontal pockets [J].

Fosse, T ;

Madinier, I ;

Hitzig, C ;

Charbit, Y .

ORAL MICROBIOLOGY AND IMMUNOLOGY, 1999, 14 (06) :352-357